140 related articles for article (PubMed ID: 36006402)
1. Relation of whole-body metabolic tumor volume and total lesion glycolysis on fluorodeoxyglucose PET/computed tomography with clinical and laboratory parameters in newly diagnosed multiple myeloma.
Goksel S; Ilkkilic K; Bulbul O; Akdogan E
Nucl Med Commun; 2022 Oct; 43(10):1077-1083. PubMed ID: 36006402
[TBL] [Abstract][Full Text] [Related]
2. Application of an artificial intelligence-based tool in [
Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Jauch A; Hajiyianni M; John L; Weinhold N; Sauer S; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3697-3708. PubMed ID: 37493665
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Total Lesion Glycolysis by
McDonald JE; Kessler MM; Gardner MW; Buros AF; Ntambi JA; Waheed S; van Rhee F; Zangari M; Heuck CJ; Petty N; Schinke C; Thanendrarajan S; Mitchell A; Hoering A; Barlogie B; Morgan GJ; Davies FE
Clin Cancer Res; 2017 Apr; 23(8):1981-1987. PubMed ID: 27698001
[No Abstract] [Full Text] [Related]
7. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
[TBL] [Abstract][Full Text] [Related]
8. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
Sun Y; Lu P; Yu L
Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
[TBL] [Abstract][Full Text] [Related]
9. Semi-quantitative FDG parameters predict survival in multiple myeloma patients without autologous stem cell transplantation.
Lee H; Hyun SH; Cho YS; Moon SH; Choi JY; Kim K; Lee KH
Cancer Imaging; 2023 Oct; 23(1):104. PubMed ID: 37891633
[TBL] [Abstract][Full Text] [Related]
10. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [
Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Mai EK; Hajiyianni M; Merz M; Raab MS; Jauch A; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38456971
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
Chung HW; Lee KY; Kim HJ; Kim WS; So Y
J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
[TBL] [Abstract][Full Text] [Related]
12. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
[TBL] [Abstract][Full Text] [Related]
13. The prognostic role of FDG PET/CT before combined radio-chemotherapy in anal cancer patients.
Leccisotti L; Manfrida S; Barone R; Ripani D; Tagliaferri L; Masiello V; Privitera V; Gambacorta MA; Rufini V; Valentini V; Giordano A
Ann Nucl Med; 2020 Jan; 34(1):65-73. PubMed ID: 31728763
[TBL] [Abstract][Full Text] [Related]
14. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of the
Goksel S; Cengiz A; Ozturk H; Yurekli Y
J Cancer Res Ther; 2021; 17(4):925-930. PubMed ID: 34528543
[TBL] [Abstract][Full Text] [Related]
17. Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma.
Terao T; Machida Y; Narita K; Kuzume A; Tabata R; Tsushima T; Miura D; Takeuchi M; Tateishi U; Matsue K
Eur Radiol; 2021 Aug; 31(8):6136-6144. PubMed ID: 33496828
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of metabolic tumour volume and total lesion glycolysis in
Jiménez-Ballvé A; García García-Esquinas M; Salsidua-Arroyo O; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Fuentes Ferrer ME; Rodríguez Rey C; Román-Santamaría JM; Moreno F; Carreras-Delgado JL
Rev Esp Med Nucl Imagen Mol; 2016; 35(6):365-372. PubMed ID: 26948652
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
20. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from
Schmidkonz C; Krumbholz M; Atzinger A; Cordes M; Goetz TI; Prante O; Ritt P; Schaefer C; Agaimy A; Hartmann W; Rössig C; Fröhlich B; Bäuerle T; Dirksen U; Kuwert T; Metzler M
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1564-1575. PubMed ID: 31853559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
